Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Todays corporate update

<< Previous

Bullboard Posts

Next >>

Comment by endpntplayon Jan 11, 2021 11:43am

173 Views

Post# 32267178

RE:Todays corporate update

Layth1990 wrote: in my opinion, the corporate update was pretty solid and honest. i invested 55k before the end of 2020 knowing covid might have a huge impact since the trial is in the us and still somehow happy seeing it is still on track.

we still have good catalysts still like partnering, and ind application acceptance by fda.

i prefer to move slow and steady than big risky jumps

yep, today's update wasn't bad. It sets expectations and provides clarity on development plans and timelines. Which is important for those considering investment. Looking forward to those near term goals!

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity